Earnings Call · Q3 FY2022·2022-11-03

Q3 22EPS +5.56%·Rev n/aQ2 22EPS +14.71%·Rev n/aQ1 22EPS -3.45%·Rev n/aQ4 21EPS +25.71%·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Louise Wilkie — Vice President of Investor Relations and Corporate Communications

Sandy Macrae — Chief Executive Officer

Nathalie Dubois-Stringfellow — Clinical Development Leader

Jason Fontenot — Chief Scientific Officer

Prathyusha Duraibabu — Chief Financial Officer

−12.8%1d on move date−14.2% vs SPY3d−16.9%5d−3.9%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access